Kiran Vij

1.6k total citations
20 papers, 614 citations indexed

About

Kiran Vij is a scholar working on Immunology, Molecular Biology and Hematology. According to data from OpenAlex, Kiran Vij has authored 20 papers receiving a total of 614 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Immunology, 7 papers in Molecular Biology and 6 papers in Hematology. Recurrent topics in Kiran Vij's work include Immune Cell Function and Interaction (6 papers), Hematopoietic Stem Cell Transplantation (4 papers) and Advanced Breast Cancer Therapies (2 papers). Kiran Vij is often cited by papers focused on Immune Cell Function and Interaction (6 papers), Hematopoietic Stem Cell Transplantation (4 papers) and Advanced Breast Cancer Therapies (2 papers). Kiran Vij collaborates with scholars based in United States, France and Canada. Kiran Vij's co-authors include David J. Lefer, Periannan Kuppusamy, Jay L. Zweíer, Michael Chzhan, E. Giannella, John F. DiPersio, Matthew Cooper, Julie Ritchey, Jaebok Choi and Jeffrey Milbrandt and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Kiran Vij

18 papers receiving 606 citations

Peers

Kiran Vij
Shu-Chi Yeh United States
L Villeneuve Canada
Erik Hofman Netherlands
Biying Xu United States
Bradley T. Schmidt United States
Stacey A. Snyder United States
Rachel J.M. Abbott United Kingdom
Sebastian Temme Germany
Herlen Alencar United States
Mariana Ozello Baratti Brazil
Shu-Chi Yeh United States
Kiran Vij
Citations per year, relative to Kiran Vij Kiran Vij (= 1×) peers Shu-Chi Yeh

Countries citing papers authored by Kiran Vij

Since Specialization
Citations

This map shows the geographic impact of Kiran Vij's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kiran Vij with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kiran Vij more than expected).

Fields of papers citing papers by Kiran Vij

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kiran Vij. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kiran Vij. The network helps show where Kiran Vij may publish in the future.

Co-authorship network of co-authors of Kiran Vij

This figure shows the co-authorship network connecting the top 25 collaborators of Kiran Vij. A scholar is included among the top collaborators of Kiran Vij based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kiran Vij. Kiran Vij is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ghai, Anchal, Christopher Egbulefu, Kvar C. L. Black, et al.. (2025). Chemo-RaST with bortezomib inhibits multiple myeloma relapse. Theranostics. 15(18). 9911–9921.
2.
Ritchey, Julie, Michael P. Rettig, Kiran Vij, et al.. (2024). Control of acute myeloid leukemia and generation of immune memory in vivo using AMV564, a bivalent bispecific CD33 x CD3 T cell engager. PLoS ONE. 19(5). e0300174–e0300174. 2 indexed citations
3.
4.
Liu, Xiuting, Graham D. Hogg, Chong Zuo, et al.. (2023). Context-dependent activation of STING-interferon signaling by CD11b agonists enhances anti-tumor immunity. Cancer Cell. 41(6). 1073–1090.e12. 53 indexed citations
5.
Kim, Sena, Boram Kim, Julie Ritchey, et al.. (2022). S100A9 upregulated by IFNGR signaling blockade functions as a novel GVHD suppressor without compromising GVL in mice. Blood. 141(8). 945–950. 1 indexed citations
6.
7.
Kim, Sena, Karl Staser, Kiran Vij, et al.. (2021). Baricitinib prevents GvHD by increasing Tregs via JAK3 and treats established GvHD by promoting intestinal tissue repair via EGFR. Leukemia. 36(1). 292–295. 16 indexed citations
8.
Cynthia, X., Vera J. Suman, A. Marilyn Leitch, et al.. (2020). ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106.. Journal of Clinical Oncology. 38(15_suppl). 504–504. 27 indexed citations
9.
Zhu, Cuige, Anna Rogers, Karama Asleh, et al.. (2020). Phospho-Ser784-VCP Is Required for DNA Damage Response and Is Associated with Poor Prognosis of Chemotherapy-Treated Breast Cancer. Cell Reports. 31(10). 107745–107745. 23 indexed citations
10.
Vij, Kiran, et al.. (2019). Reactivity with the EpCAM-specific antibodies MOC-31 and Ber-Ep4 in plasma cell neoplasms: a potential diagnostic pitfall in cytology samples. Journal of the American Society of Cytopathology. 8(5). 265–269. 1 indexed citations
11.
Xu, Mina L., Eric D. Hsi, Yuri Fedoriw, et al.. (2019). Practical Approaches on CD30 Detection and Reporting in Lymphoma Diagnosis. The American Journal of Surgical Pathology. 44(2). e1–e14. 17 indexed citations
12.
Goldsmith, Scott, Sana Rehman, Cara Lunn Shirai, Kiran Vij, & John F. DiPersio. (2019). Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib. Blood Advances. 3(23). 4131–4135. 33 indexed citations
13.
Choi, Jaebok, Matthew Cooper, Karl Staser, et al.. (2018). Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease. Leukemia. 32(11). 2483–2494. 66 indexed citations
14.
Cooper, Matthew, Jaebok Choi, Darja Karpova, et al.. (2017). Azacitidine Mitigates Graft-versus-Host Disease via Differential Effects on the Proliferation of T Effectors and Natural Regulatory T Cells In Vivo. The Journal of Immunology. 198(9). 3746–3754. 32 indexed citations
15.
Bagegni, Nusayba A., Shana Thomas, Ning Liu, et al.. (2017). Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib. Breast Cancer Research. 19(1). 123–123. 53 indexed citations
16.
Esser, Alison K., Daniel A. Rauch, Jingyu Xiang, et al.. (2017). HTLV-1 viral oncogene HBZ induces osteolytic bone disease in transgenic mice. Oncotarget. 8(41). 69250–69263. 12 indexed citations
17.
Choi, Jaebok, Matthew Cooper, Kiran Vij, et al.. (2016). Pharmacologic Co-Blockade of IFNγR and IL6R Pathways to Prevent and Treat GvHD. Blood. 128(22). 3353–3353. 3 indexed citations
18.
Vij, Kiran & Hanlin L. Wang. (2008). Aberrant Expression of α-Fetoprotein in Intrahepatic Cholangiocarcinoma: An Exceptional Occurrence. International Journal of Surgical Pathology. 16(2). 194–198. 3 indexed citations
19.
Jain, Sanjay, C.K. Naughton, Mao Yang, et al.. (2004). Mice expressing a dominant-negative Ret mutation phenocopy human Hirschsprung disease and delineate a direct role of Ret in spermatogenesis. Development. 131(21). 5503–5513. 103 indexed citations
20.
Kuppusamy, Periannan, Michael Chzhan, Kiran Vij, et al.. (1994). Three-dimensional spectral-spatial EPR imaging of free radicals in the heart: a technique for imaging tissue metabolism and oxygenation.. Proceedings of the National Academy of Sciences. 91(8). 3388–3392. 166 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shu-Chi Yeh Breakdown of academic impact, for papers by L Villeneuve Breakdown of academic impact, for papers by Erik Hofman Breakdown of academic impact, for papers by Biying Xu Breakdown of academic impact, for papers by Bradley T. Schmidt Breakdown of academic impact, for papers by Stacey A. Snyder Breakdown of academic impact, for papers by Rachel J.M. Abbott Breakdown of academic impact, for papers by Sebastian Temme Breakdown of academic impact, for papers by Herlen Alencar Breakdown of academic impact, for papers by Mariana Ozello Baratti
Rankless by CCL
2026